|
1
|
Design and endpoints of clinical trials in hepatocellular carcinoma.
|
J Natl Cancer Inst
|
2008
|
11.27
|
|
2
|
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
|
Nat Med
|
2004
|
9.80
|
|
3
|
Biomarkers of response and resistance to antiangiogenic therapy.
|
Nat Rev Clin Oncol
|
2009
|
4.17
|
|
4
|
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
|
J Clin Oncol
|
2005
|
3.83
|
|
5
|
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
|
J Natl Compr Canc Netw
|
2009
|
3.25
|
|
6
|
Hepatocellular carcinoma: the need for progress.
|
J Clin Oncol
|
2005
|
3.11
|
|
7
|
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
|
Oncologist
|
2011
|
3.05
|
|
8
|
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
|
Ann Surg
|
2015
|
2.79
|
|
9
|
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
|
Cancer Res
|
2008
|
2.71
|
|
10
|
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
|
J Clin Oncol
|
2007
|
2.33
|
|
11
|
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.
|
Cancer
|
2009
|
2.19
|
|
12
|
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.
|
J Clin Oncol
|
2011
|
2.13
|
|
13
|
Systemic therapy for biliary tract cancers.
|
Oncologist
|
2008
|
1.98
|
|
14
|
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience.
|
Radiology
|
2007
|
1.87
|
|
15
|
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
|
J Clin Oncol
|
2006
|
1.86
|
|
16
|
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
|
Cancer Res
|
2012
|
1.83
|
|
17
|
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
|
Oncologist
|
2013
|
1.76
|
|
18
|
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
|
Clin Cancer Res
|
2010
|
1.71
|
|
19
|
Genetics of biliary tract cancers and emerging targeted therapies.
|
J Clin Oncol
|
2010
|
1.69
|
|
20
|
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
|
J Clin Oncol
|
2006
|
1.64
|
|
21
|
A proposed staging system for intrahepatic cholangiocarcinoma.
|
Ann Surg Oncol
|
2008
|
1.64
|
|
22
|
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
|
Oncology
|
2009
|
1.63
|
|
23
|
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
|
Histopathology
|
2010
|
1.48
|
|
24
|
Targeting the HGF/c-MET pathway in hepatocellular carcinoma.
|
Clin Cancer Res
|
2013
|
1.39
|
|
25
|
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
|
BMC Cancer
|
2011
|
1.36
|
|
26
|
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
|
Clin Cancer Res
|
2014
|
1.33
|
|
27
|
Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
|
Invest Radiol
|
2012
|
1.33
|
|
28
|
Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer.
|
Ann Surg
|
2005
|
1.30
|
|
29
|
Intrahepatic cholangiocarcinoma.
|
Surg Clin North Am
|
2010
|
1.27
|
|
30
|
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
|
Expert Rev Anticancer Ther
|
2009
|
1.26
|
|
31
|
Gemcitabine-associated thrombotic microangiopathy.
|
Cancer
|
2004
|
1.26
|
|
32
|
Targeting insulin-like growth factor axis in hepatocellular carcinoma.
|
J Hematol Oncol
|
2011
|
1.22
|
|
33
|
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
|
Cancer
|
2011
|
1.20
|
|
34
|
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
|
Hepatology
|
2014
|
1.16
|
|
35
|
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
|
Dig Dis Sci
|
2007
|
1.15
|
|
36
|
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
|
Hepatology
|
2014
|
1.15
|
|
37
|
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
|
Oncologist
|
2009
|
1.14
|
|
38
|
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
1.11
|
|
39
|
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
|
Hepatology
|
2015
|
1.11
|
|
40
|
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.
|
JAMA Surg
|
2014
|
1.11
|
|
41
|
Cholangiocarcinoma: current and novel imaging techniques.
|
Radiographics
|
2008
|
1.09
|
|
42
|
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
|
Dig Dis Sci
|
2006
|
1.09
|
|
43
|
Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
|
Oncologist
|
2009
|
1.09
|
|
44
|
Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.
|
Ann Surg Oncol
|
2013
|
1.05
|
|
45
|
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
|
PLoS One
|
2012
|
1.05
|
|
46
|
Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.
|
J Hepatol
|
2012
|
1.03
|
|
47
|
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.
|
Liver Transpl
|
2004
|
1.02
|
|
48
|
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
|
Clin Cancer Res
|
2008
|
1.01
|
|
49
|
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
|
Oncologist
|
2011
|
0.98
|
|
50
|
Mutational analysis and clinical correlation of metastatic colorectal cancer.
|
Cancer
|
2014
|
0.98
|
|
51
|
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
|
J Hematol Oncol
|
2013
|
0.97
|
|
52
|
Recurrence after operative management of intrahepatic cholangiocarcinoma.
|
Surgery
|
2013
|
0.96
|
|
53
|
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups.
|
N Engl J Med
|
2005
|
0.96
|
|
54
|
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
|
Crit Rev Oncol Hematol
|
2007
|
0.95
|
|
55
|
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
|
Cancer
|
2006
|
0.95
|
|
56
|
Hepatobiliary cancers, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.93
|
|
57
|
Targeted therapy for biliary tract cancers.
|
J Hepatobiliary Pancreat Sci
|
2012
|
0.92
|
|
58
|
Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
|
Cardiovasc Intervent Radiol
|
2013
|
0.92
|
|
59
|
A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma.
|
Oncologist
|
2011
|
0.91
|
|
60
|
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
|
Invest New Drugs
|
2009
|
0.89
|
|
61
|
Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions.
|
Radiology
|
2014
|
0.88
|
|
62
|
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
|
J Hematol Oncol
|
2009
|
0.87
|
|
63
|
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
|
Clin Colorectal Cancer
|
2006
|
0.85
|
|
64
|
Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.
|
Gastrointest Cancer Res
|
2011
|
0.84
|
|
65
|
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
|
Cancer
|
2013
|
0.84
|
|
66
|
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
|
Cancer Lett
|
2006
|
0.84
|
|
67
|
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
|
Oncologist
|
2013
|
0.83
|
|
68
|
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
|
Oncology
|
2012
|
0.83
|
|
69
|
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
|
J Gastrointest Cancer
|
2014
|
0.83
|
|
70
|
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
|
Clin Cancer Res
|
2003
|
0.82
|
|
71
|
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
|
Invest New Drugs
|
2014
|
0.81
|
|
72
|
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.81
|
|
73
|
Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward?
|
J Clin Oncol
|
2012
|
0.80
|
|
74
|
Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib.
|
Dig Dis Sci
|
2014
|
0.80
|
|
75
|
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
|
Clin Colorectal Cancer
|
2006
|
0.80
|
|
76
|
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.
|
Endocr Relat Cancer
|
2012
|
0.80
|
|
77
|
Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation.
|
JAMA
|
2008
|
0.80
|
|
78
|
Microsatellite instability in gallbladder carcinoma.
|
Virchows Arch
|
2015
|
0.80
|
|
79
|
Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?
|
Diagn Interv Radiol
|
2015
|
0.79
|
|
80
|
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.79
|
|
81
|
Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.
|
J Vasc Interv Radiol
|
2013
|
0.78
|
|
82
|
IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
|
Expert Rev Anticancer Ther
|
2012
|
0.78
|
|
83
|
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.77
|
|
84
|
Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
|
J Gastrointest Cancer
|
2009
|
0.77
|
|
85
|
Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.
|
AJR Am J Roentgenol
|
2015
|
0.77
|
|
86
|
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
|
Cancer Chemother Pharmacol
|
2013
|
0.77
|
|
87
|
Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations.
|
Pancreatology
|
2005
|
0.76
|
|
88
|
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
|
HPB (Oxford)
|
2010
|
0.75
|
|
89
|
Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma?
|
Cancer
|
2003
|
0.75
|
|
90
|
Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?
|
Am J Clin Oncol
|
2015
|
0.75
|
|
91
|
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2005
|
0.75
|
|
92
|
Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
|
Nature
|
2015
|
0.75
|
|
93
|
Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival.
|
J Comput Assist Tomogr
|
2015
|
0.75
|
|
94
|
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
|
Am J Clin Oncol
|
2017
|
0.75
|
|
95
|
Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
|
Expert Rev Anticancer Ther
|
2008
|
0.75
|
|
96
|
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
|
Cell Rep
|
2017
|
0.75
|
|
97
|
Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells?
|
Am J Clin Oncol
|
2015
|
0.75
|